Multi-Drug Resistant Organism Focus
OpGen is focused on combating life-threatening, antibiotic-resistant infections using molecular diagnostics and bioinformatics technologies. Our CLIA-certified diagnostic laboratory helps hospital staff to diagnose, prevent, and manage acute infections. We have extensive experience in the fields of microbial genetics, molecular diagnostics, and bioinformatics, and have developed The Acuitas™ MDRO Gene Test that directly detects seven critical multi-drug resistant organism (MDRO) genes including those associated with Gram-negative carbapenem resistant enterobacteriaceae (CRE). The test detects the genes directly from a single patient swab or clinical isolate and test results are provided to client hospitals within 24 hours of sample receipt. We also provide follow-on testing that combines organism ID, antibiotics susceptibility testing, and DNA sequence-based information when needed. Our Lighthouse™ MDRO Management System is a bioinformatics tool that combines test results and hospital data to provide clients with real-time detection, monitoring, and management capabilities for identifying and tracking dangerous MDROs in their institution and guiding antibiotic stewardship programs.
OpGen’s Whole Genome Mapping technology, provides innovative tools for microbial genomic sequence assembly and finishing, strain comparison and species characterization for customers focused on DNA sequencing, epidemiology, outbreak identification, microbial forensics, biodefense and pharmaceutical discovery.
OpGen, Inc. is a privately held, microbial genetics analysis company headquartered in Gaithersburg, Maryland. The company was founded in January 2002 by the Wisconsin Alumni Research Foundation (WARF), with the objectives of developing and commercializing products and services based on the proprietary Whole Genome Mapping technology for the high-precision microbial analysis market. The technology continues to be used today for the automated assembly and analysis of genomes by the world’s most prestigious sequencing centers. Additional applications developed for Whole Genome Mapping include microbial strain typing and comparative genomics. In 2011, the company expanded applications offered to encompass the assembly of large genomes such as those of humans, plants and animals. In 2013, The OpGen Clinical Services Laboratory achieved CLIA-certification and began offering testing services to address hospital-acquired infections (HAIs). The Acuitas MDRO Gene Test, the first to test seven critical MDRO genes from one patient swab, was launched in early 2014.
The company’s corporate offices, commercial MapIt® laboratory, and CLIA-certified Clinical Services Laboratory are located in Gaithersburg, Maryland.
Our Journey Forward
We believe that no patient should suffer from a life-threatening, drug-resistant infection and we aim to transform infectious disease management through innovation in microbiology, molecular diagnostics, and information technologies. We invest to develop state-of-the-art tests with in-depth validation of clinical performance. Our centralized testing capabilities provide affordable, highly accurate molecular testing to healthcare providers and public health laboratories.